NeuroLux

NeuroLux operates in a specialized segment of neuroscience research tools: wireless optogenetics and implantable systems for experiments involving freely moving animals. Its described offering combines implants with wireless power delivery, control hardware, antennas, software, and physiological monitoring, creating an integrated research setup rather than a single standalone device. Specific differentiators include battery-free implant configurations for brain, spinal, and peripheral targets; modular control across multiple cages; and nVital’s wireless collection of temperature and motion data. It also does not provide comparative pricing, customer counts, market share, or independent performance benchmarks. NeuroLux is categorized as biotechnology and has an employee-size range of 1–10, suggesting a small specialist operation rather than a broad life-sciences platform. Its position is therefore best described by its technical focus and integrated product scope, not by a demonstrated lead over named competitors.

NeuroLux’s observable trajectory combines early public research funding with a portfolio of specialized research hardware. The earliest disclosed grant in the funding history is a $1.5 million Phase II SBIR Grant led by the National Institute of Mental Health on Aug 4, 2017; a Phase I STTR Grant led by the National Institutes of Health is dated Oct 19, 2017, but its amount is undisclosed. The product descriptions span implantable optogenetic devices, wireless power and control systems, a modular setup for parallel cage experiments, and nVital physiological monitoring. Consequently, the record supports a picture of focused technical development, not a measurable recent acceleration in headcount, financing, or commercialization.